| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 115 |
| 1 | NIVOLUMAB | 58 |
| 2 | CARBOPLATIN | 44 |
| 3 | IPILIMUMAB | 33 |
| 4 | PACLITAXEL | 30 |
| 5 | PACLITAXEL (AIBUMIN-BOUND) | 30 |
| 6 | PEMETREXED DISODIUM | 14 |
| 7 | PEMETREXED | 12 |
| 8 | ATEZOLIZUMAB | 8 |
| 9 | DEXAMETHASONE | 7 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | DOSTARLIMAB | 5 | 0.0020 |
| 1 | NALDEMEDINE | 3 | 0.0018 |
| 2 | BETHANECHOL CHLORIDE | 1 | 0.0018 |
| 3 | CEMIPLIMAB-RWLC | 3 | 0.0014 |
| 4 | PEMBROLIZUMAB | 115 | 0.0011 |
| 5 | IPILIMUMAB | 33 | 0.0008 |
| 6 | VONOPRAZAN FUMARATE | 5 | 0.0006 |
| 7 | NIVOLUMAB | 58 | 0.0006 |
| 8 | APREPITANT | 4 | 0.0005 |
| 9 | PEGFILGRASTIM | 6 | 0.0005 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 177 | 0.0018 |
| 1 | CTLA-4-directed Blocking Antibody [EPC] | 34 | 0.0007 |
| 2 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 4 | 0.0005 |
| 3 | Microtubule Inhibitor [EPC] | 30 | 0.0002 |
| 4 | Platinum-based Drug [EPC] | 47 | 0.0002 |
| 5 | Programmed Death Ligand-1 Blocker [EPC] | 3 | 0.0001 |
| 6 | Antimalarial [EPC] | 1 | 0.0001 |
| 7 | Antiprotozoal [EPC] | 1 | 0.0001 |
| 8 | Leukocyte Growth Factor [EPC] | 7 | 0.0000 |
| 9 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 1 | 0.0000 |